N-{1-[4-(5-isopropyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-phenyl]-cyclohexylmethyl}-acetamide | 933063-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{1-[4-(5-isopropyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-phenyl]-cyclohexylmethyl}-acetamide
• 英文别名: N-[[1-[4-[(5-propan-2-yl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]cyclohexyl]methyl]acetamide
• CAS: 933063-45-7
• 化学式: C₂₀H₂₈N₄O₃S₂
• 分子量: 436.599
• InChiKey: RTEIKDOXMNJDPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-{1-[4-(5-isopropyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-phenyl]-cyclohexylmethyl}-acetamide 在 盐酸 、 水 作用下， 反应 20.0h， 生成 4-(1-aminomethyl-cyclohexyl)-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)-benzenesulfonamide hydrochloride
  参考文献：
  名称：

  WO2007/39173

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-5-异丙基-1,3,4-噻二唑 、 4-[1-(acetylamino-methyl)-cyclohexyl]-benzenesulfonyl chloride 在 吡啶 作用下， 反应 15.0h， 生成 N-{1-[4-(5-isopropyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-phenyl]-cyclohexylmethyl}-acetamide
  参考文献：
  名称：

  WO2007/39173

  摘要：

  公开号：

文献信息

• CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF
  申请人：SCHOENAFINGER Karl

  公开号：US20080280959A1

  公开（公告）日：2008-11-13

  The present invention comprises cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their functional derivatives as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various R1-R9 substituents are defined herein. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明包括环状N-[1,3,4]-噻二唑-2-基苯磺酰胺，它们的功能衍生物以及其生理上可接受的盐和药物组成物，具有过氧化物酶体增殖物激活受体（PPAR）PPARδ和PPARγ激动剂活性。该发明化合物的结构由下式I定义，其中各种R1-R9取代基在此定义。本发明还揭示了化合物的制备过程。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病。
• Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof
  申请人：Sanofi-aventis

  公开号：US07683181B2

  公开（公告）日：2010-03-23

  The present invention comprises cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their functional derivatives as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various R1-R9 substituents are defined herein. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺、它们的功能衍生物以及其生理上可接受的盐和制药组合物，具有过氧化物酶体增殖物激活受体（PPAR）PPARδ和PPARγ激动剂活性。本发明化合物的结构由下式I定义，其中各种R1-R9取代基在此定义。本发明还公开了该化合物的制备方法。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗的疾病以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi-Aventis

  公开号：EP1937659A1

  公开（公告）日：2008-07-02
• CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi-Aventis

  公开号：EP1937659B1

  公开（公告）日：2010-11-10
• US7683181B2
  申请人：——

  公开号：US7683181B2

  公开（公告）日：2010-03-23